Abstract
Background Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections occur frequently among end-stage renal disease (ESRD) patients. We analyzed our data to address concern that these patients are at increased risk for mortality or allograft dysfunction after renal transplantation compared with noninfected patients. Patients and Methods We retrospectively compared outcomes and survivals among 1350 patients who received renal allografts from 1990 to 2006. Results Fourteen patients were positive for both hepatitis B surface antigen (HBsAg) and HCV antibody (anti-HCV; group 1); 23 were HBsAg-positive and anti-HCV-negative (group 2); 29 were HBsAg-negative and anti-HCV-positive (group 3); and 1284 were negative for both markers (group 4). With respect to mean serum creatinine, there were significant differences between groups 1 and 4 ( P < .01), and groups 2 and 4 ( P < .01), but no significant difference between groups 3 and 4. With respect to graft survival, there were significant differences between groups 1 and 4 ( P < .01), and between groups 2 and 4 ( P < .01). There was no significant difference for survival among groups. Conclusions HBV or HCV infections are not a contraindication to kidney transplantation in Iranian patients; they had no effect on patient survival. However, allograft outcomes were worse among HBV- or HCV-infected patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
